Share on StockTwits

IDEXX Laboratories (NASDAQ:IDXX) Director M Anne Szostak purchased 2,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were purchased at an average price of $127.03 per share, for a total transaction of $254,060.00. Following the completion of the transaction, the director now directly owns 7,000 shares in the company, valued at approximately $889,210. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of IDEXX Laboratories (NASDAQ:IDXX) opened at 126.34 on Monday. IDEXX Laboratories has a 52-week low of $92.09 and a 52-week high of $140.00. The stock’s 50-day moving average is $130.4 and its 200-day moving average is $126.4. The company has a market cap of $6.351 billion and a price-to-earnings ratio of 34.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, July 25th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.05. The company had revenue of $390.00 million for the quarter, compared to the consensus estimate of $385.20 million. During the same quarter in the previous year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts predict that IDEXX Laboratories will post $3.85 earnings per share for the current fiscal year.

A number of research firms have recently commented on IDXX. Analysts at Piper Jaffray raised their price target on shares of IDEXX Laboratories from $125.00 to $126.00 in a research note on Monday, July 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of IDEXX Laboratories in a research note on Wednesday, July 16th. They now have a $139.00 price target on the stock. Finally, analysts at Canaccord Genuity upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, June 24th. They now have a $148.00 price target on the stock, up previously from $116.00. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. IDEXX Laboratories has a consensus rating of “Hold” and an average target price of $136.60.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.